Elsevier

Pathology

Volume 47, Issue 4, June 2015, Pages 314-319
Pathology

Evaluation of p16INK4a immunostaining for the detection of high-grade changes in cervical cytology

https://doi.org/10.1097/PAT.0000000000000249Get rights and content

Summary

Since its introduction in Australia in 2007, the human papillo-mavirus (HPV) vaccine has led to a markedly lower prevalence of vaccine targeted HPV genotype infections as well as HPV disease including genital warts and histologically confirmed high-grade (HG) cervical abnormalities. To increase the ability to identify abnormal cells in lower prevalence, adjunct markers can be incorporated to improve the sensitivity and specificity of cytology test. One such marker is p16INK4a(p16), which is detectable in cells expressing the E7 oncogene encoded by high-risk HPVs (HR-HPV). In this study, the sensitivity and specificity of p16 immunostaining in detection of underlying HG lesions was evaluated in a cohort of 454 women undergoing surgical treatment for biopsy proven cervical dysplasia. Overall, p16 positive cells were detected in 321 (71%) of cytology preparations evaluated. Comparison of p16 staining on cytological preprations to histology diagnosis available on 212 patients, showed 26 (54%), 41 (78%) and 80 (90%) of cytology preparations to be p16 positive in women with CIN1, CIN2 and CIN3, respectively (p < 0.005). HPV16 and 18 were the most prevalent genotypes in HG lesions and were highly correlated with p16 staining. p16 staining provides an additional marker which can assist in better detecting underlying HG lesion in cytology smears with low disease prevalence.

References (46)

  • M.T. Fahey et al.

    Meta-analysis of Pap test accuracy

    Am J Epidemiol

    (1995)
  • J.M. Brotherton et al.

    Human papillomavirus (HPV) vaccination coverage in young Australian women is higher than previously estimated: independent estimates from a nationally representative mobile phone survey

    Vaccine

    (2013)
  • S.N. Tabrizi et al.

    Fall in human papillomavirus prevalence following a national vaccination program

    J Infect Dis

    (2012)
  • M.J. Thrall et al.

    High-risk HPV testing inwomen 30 years or older with negative Papanicolaou tests: initial clinical experience with 18-month follow-up

    Am J Clin Pathol

    (2010)
  • D. Mesher et al.

    Long-term follow-up of cervical disease in women screened by cytology and HPV testing: results from the HART study

    Br J Cancer

    (2010)
  • M.P. Stevens et al.

    HPV genotype prevalence in women with abnormal pap smears in Melbourne, Australia

    J Med Virol

    (2009)
  • T.C. Wright et al.

    The ATHENA human papillomavirus study: design, methods, and baseline results

    Am J Obstet Gynecol

    (2012)
  • D.KR. Lowy et al.

    Genital human papillomavirus infection

    Proc Natl Acad Sci USA

    (1994)
  • U. Schubert et al.

    Rapid degradation of a large fraction of newly synthesized proteins by proteasomes

    Nature

    (2000)
  • T. Sano et al.

    Overexpression of p16 and p14ARF is associated with human papillomavirus infection in cervical squamous cell carcinoma and dysplasia

    Pathol Int

    (2002)
  • R. Klaes et al.

    Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri

    Int J Cancer

    (2001)
  • S.N. Khleif et al.

    Inhibition of cyclin D-CDK4/CDK6 activity is associated with an E2F-mediated induction of cyclin kinase inhibitor activity

    Proc Natl Acad Sci USA

    (1996)
  • Y. Nakao et al.

    Induction of p16 during immortalization by HPV 16 and 18 and not during malignant transformation

    Br J Cancer

    (1997)
    • View full text
    Copyright © 2015 Royal College of Pathologists of Australasia. Published by Elsevier B.V. All rights reserved.